Pharmacist Medication Insights: for Panzyga for Primary Humoral Immunodeficiency

Author(s):

Saro Arakelians, PharmD

Panzyga is indicated for the treatment of primary humoral immunodeficiency, chronic inflammatory demyelinating polyneuropathy, and chronic immune thrombocytopenia.

Panzyga (immune globulin intravenous [Human]-ifas) is indicated for the following:

For the treatment of adults 18 years of age and older with chronic inflammatory demyelinating polyneuropathy (CIDP) to improve neuromuscular disability and impairment.
Primary humoral immunodeficiency (PI) in patients 2 years of age and older.
Chronic immune thrombocytopenia (ITP) in adults.

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!

Pharmacist Medication Insights: for Panzyga for Primary Humoral Immunodeficiency

Newsletter